
|Articles|September 1, 2006
Taxane-refractory PCa: Regimens offer modest results
Atlanta-A trial of drug regimens in hormone-refractory prostate cancer came up with only modest results, but it did take an important first step: It is one of the first prospective trials conducted in taxane-refractory disease.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
2
Study suggests potential diuretic effect with nadofaragene firadenovec
3
Nicole L. Miller, MD, FACS, on assessing patients after BPH treatment failure
4
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
5











